Frankfurt - Delayed Quote EUR

TG Therapeutics, Inc. (NKB2.F)

35.26

+0.90

+(2.63%)

At close: April 25 at 8:06:17 AM GMT+2

Exploring US High Growth Tech Stocks

Over the last 7 days, the United States market has experienced a 3.0% drop, although it has risen by 4.6% over the past year, with earnings anticipated to grow by 14% annually in the coming years. In this context of fluctuating yet optimistic growth prospects, identifying high-growth tech stocks requires careful consideration of their innovation potential and ability to capitalize on emerging trends within a dynamic market environment.

Simply Wall St. 9 days ago

LEGN

TGTX

NFLX
TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

Strong adoption of TGTX's sole marketed product, Briumvi, approved for treating relapsing forms of multiple sclerosis, is driving the top line.

Zacks 16 days ago

TGTX
TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, April 10, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), announced the presentation of data yesterday highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting. Links to each presentation are included below. Michael S. Weiss, Chief Executive Officer and Chairman of TG Therapeutics stated, "We are encouraged by the results from the ENHANCE trial presented yesterday, whic

GlobeNewswire 16 days ago

TGTX
TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

NEW YORK, April 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the publication of two journal articles one describing the evolution of CD20 treatments for multiple sclerosis (MS) and the other detailing the experience of seven individuals with MS who switched to BRIUMVI® (ublituximab-xiiy) from a different anti-CD20 monoclonal antibody therapy due to efficacy or tolerability concerns. Details of the publications are provided below. Michael S. Weiss, the Company

GlobeNewswire 19 days ago

TGTX
IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche

TG Therapeutics rallied Wednesday after Roche's rival multiple sclerosis treatment, Ocrevus, missed its mark in a study.

Investor's Business Daily 23 days ago

TGTX
Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%?

While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...

Simply Wall St. 27 days ago

TGTX
These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles

Insurance stock Root soared to a new high on Friday. The IBD 50 holding has an ideal Composite and Relative Strength Rating.

Investor's Business Daily last month

KRMN

ROOT

TGTX
TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts

We recently shared a list of 10 Best Short Squeeze Stocks To Buy According to Analysts. In this article, we will see how TG Therapeutics, Inc. (NASDAQ:TGTX) compares to the other top short squeeze stocks that have received a Buy rating from analysts. Stock market trading has an ever-changing environment. Short squeeze is among the […]

Insider Monkey last month

TGTX
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

TG Therapeutics (TGTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Zacks last month

TGTX

CUE
Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025?

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other best performing growth stocks in 2025. Heavy AI investments and the tariffs uncertainty have been putting pressure on the technology and growth sector. […]

Insider Monkey last month

TGTX
Biotech Stock TG Therapeutics Hits A High In Market Meltdown

Biotech stock TG Therapeutics is outperforming the major indexes in a declining stock market. TGTX stock hit a new high on Friday.

Investor's Business Daily last month

TGTX
TG Therapeutics (NasdaqCM:TGTX) Surges 28% Following US$23 Million Net Income Turnaround

TG Therapeutics (NasdaqCM:TGTX) saw its share price surge by 28% last week following a robust earnings announcement. The company's fourth-quarter revenue grew by 146% year-over-year, accompanied by a turnaround from a net loss to a net income of $23 million. Such performance undoubtedly bolstered investor confidence, coinciding with the company’s updated guidance projecting $540 million in global revenue with significant contributions from the BRIUMVI product. The positive financial results...

Simply Wall St. last month

TGTX
S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout

S&P 500 members Intercontinental Exchange and Allstate lead this weekend's watch list of five stocks near buy points, showing resilience amid a market shakeout. The list also includes TG Therapeutics, fitness-club operator Life Time Group and aerospace supplier Heico, which Warren Buffett's Berkshire Hathaway has bought recently. TGTX is part of IBD's Leaderboard portfolio of elite stocks that has currently been winnowed down to just eight names.

Investor's Business Daily last month

LTH

ALL

ALL-PH
Why TG Therapeutics Stock Was Soaring This Week

Following news of an estimates-topping fourth quarter, TG Therapeutics (NASDAQ: TGTX) stock was a hot item with investors over the past few days. According to data compiled by S&P Global Market Intelligence, as of mid-afternoon Friday, the biotech's share price had risen by almost 27% week to date. TG Therapeutics got the ball rolling before the trading week kicked off, publishing its Q4 and full-year 2024 results Monday morning.

Motley Fool last month

TGTX
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in patients with relapsing forms of multiple sclerosis (RMS), at the American Academy of Neurology 2025 annual meeting, being held April 5 - 9, 2025, in San Diego, California. Abstracts are now available online and can be accessed on the AAN meeting website at https://www.aan.com/events/annual-meeting-abstracts. De

GlobeNewswire last month

TGTX
This Biotech Stock Hits Buy Point After Earnings Burst

TGTX stock is climbing and broke out of a base Thursday. TG Therapeutics reported a robust earnings report on Monday.

Investor's Business Daily last month

TGTX
Exploring 3 High Growth Tech Stocks In The US Market

Over the last 7 days, the United States market has experienced a 2.5% drop, yet it remains up by 13% over the past year with earnings forecasted to grow by 14% annually. In this context, identifying high growth tech stocks involves examining companies that demonstrate strong potential for expansion and innovation amidst these dynamic market conditions.

Simply Wall St. last month

WAY

EXEL

TGTX
Why TG Therapeutics, Inc. (TGTX) Surged On Monday?

We recently published a list of 10 Stocks Lead Monday’s Charge Amid Market Bloodbath. In this article, we are going to take a look at where TG Therapeutics, Inc. (NASDAQ:TGTX) stands against other stocks that lead Monday’s charge amid market bloodbath. The stock market kicked off the trading week in a bloodbath, erasing last week’s […]

Insider Monkey last month

TGTX
Company News for Mar 4, 2025

Companies In The News Are: CRC, TGTX, NOMD, BHVN.

Zacks last month

TGTX

CRC

NOMD
TG Therapeutics Inc (TGTX) Q4 2024 Earnings Call Highlights: Strong U.S. ...

TG Therapeutics Inc (TGTX) reports robust financial performance with significant growth in BRIUMVI sales and outlines ambitious plans for 2025.

GuruFocus.com last month

TGTX

Performance Overview

Return	NKB2.F	S&P 500 (^GSPC)
YTD	+13.96%	-6.06%
1-Year	+176.16%	+9.44%
3-Year	+424.08%	+28.61%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

TG Therapeutics, Inc. (NKB2.F)

Exploring US High Growth Tech Stocks

TG Therapeutics Shares Rise Almost 30% in 3 Months: Here's Why

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

IBD 50 Stock TG Therapeutics Rallies On A Setback For Chief Rival Roche

Should We Be Cautious About TG Therapeutics, Inc.'s (NASDAQ:TGTX) ROE Of 11%?

These Insurance Stocks And Biotech Leader Hit New Highs As Stock Market Crumbles

TG Therapeutics (TGTX): Among the Best Short Squeeze Stocks to Buy According to Analysts

Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength?

Is TG Therapeutics, Inc. (TGTX) the Best Performing Growth Stock in 2025?

Biotech Stock TG Therapeutics Hits A High In Market Meltdown

TG Therapeutics (NasdaqCM:TGTX) Surges 28% Following US$23 Million Net Income Turnaround

S&P 500 Pair, Warren Buffet Pick Lead Five Stocks Near Buy Points Amid Market Shakeout

Why TG Therapeutics Stock Was Soaring This Week

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

This Biotech Stock Hits Buy Point After Earnings Burst

Exploring 3 High Growth Tech Stocks In The US Market

Why TG Therapeutics, Inc. (TGTX) Surged On Monday?

Company News for Mar 4, 2025

TG Therapeutics Inc (TGTX) Q4 2024 Earnings Call Highlights: Strong U.S. ...

Performance Overview